Latigo Biotherapeutics, Inc.
Latigo Biotherapeutics, Inc. scores highest on Anchor (53) and lowest on Price (0). Its PosiPenta is 26.19 out of 100, weaker than most similar companies.
On the Penta Grid this week, Latigo Biotherapeutics, Inc. is Grid #804 of 837 in the Healthcare sector in United States, and Grid #3,785 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Latigo Biotherapeutics, Inc. | 26.19 | 0 | 30 | 40 | 8 | 53 |
| Amphastar Pharmaceuticals, Inc. | 70.81 | 70 | 80 | 87 | 52 | 66 |
| Seaport Therapeutics, Inc. | 46.69 | 0 | 37 | 57 | 73 | 67 |
| Vor Biopharma Inc. | 61.13 | 48 | 53 | 63 | 92 | 49 |
| IRADIMED CORPORATION | 65.14 | 16 | 67 | 75 | 90 | 78 |
| STAAR Surgical Company | 55.20 | 24 | 87 | 58 | 63 | 43 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -5.56 |
| P/B ratio | -3.36 |
EEarnings
| Trailing EPS | ₹-238.68 |
| Forward EPS | ₹-197.95 |
NNitro
| Price | 1326.01 |
| 52-week high | 2455.96 |
| 52-week low | 1278.65 |
| Fall from 52-week high | 46.0% |
TTorque
| Return on equity (ROE) | — |
| Debt-to-equity | 2.50 |
AAnchor
| Beta (price swings) | — |
| Market cap | ₹8,791 Cr |
| Insider holding | 4.98% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Latigo Biotherapeutics, Inc.'s PosiPenta score?
Latigo Biotherapeutics, Inc.'s PosiPenta is 26.19 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Latigo Biotherapeutics, Inc. stand on the Penta Grid?
On the Penta Grid this week, Latigo Biotherapeutics, Inc. is Grid #804 of 837 in the Healthcare sector in United States, and Grid #3,785 of 4,000 in United States.
Which PosiPenta pillar is strongest for Latigo Biotherapeutics, Inc.?
Anchor (stability and dividends), with a score of 53 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for Latigo Biotherapeutics, Inc.?
Price (valuation), with a score of 0 out of 100: much weaker than most similar companies.
PositoAI is for research and education only and is not investment advice.